Skip to main content

Table 3 Paraclinical characteristics

From: Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial

 

Total (n = 192)

Intervention group (n = 95)

Control group (n = 97)

Standardized difference

CAC score, median (IQR)

26 (0 – 214.5)

17 (0 – 211)

43 (0 – 234)

N/A

Adjusted CAC score, median (IQR)

42 (0 – 78)

39 (0 – 68)

55 (0 – 80)

N/A

CAC score > 400

29

14

15

0.02

Systolic blood pressure, mmHg

137 (18)

137 (17)

138 (19)

0.07

Heart rate, bpm

78 (15)

77 (12)

78 (17)

0.07

Creatinine, mg/dL

76 (21)

76 (21)

75 (20)

-0.04

HbA1c, mmol/mol

40 (9)

39 (8)

41 (9)

0.22

Lipid profile, mmol/L

 Cholesterol

4.8 (1.1)

4.8 (1.1)

4.8 (1.1)

-0.02

 HDL

1.4 (0.4)

1.4 (0.4)

1.4 (0.5)

0.02

 LDL

3.1 (1.0)

3.1 (1.1)

3.0 (1.0)

-0.06

 Triglyceride

1.9 (1.1)

1.9 (1.0)

1.9 (1.1)

-0.04

  1. Baseline CAC score, blood pressure and heart rate and laboratory data for all patients and stratified by randomization group. Data are presented as mean (SD) or median [IQR] as appropriate
  2. Abbreviations: CAC Coronary artery calcium, HbA1c hemoglobin A1c, HDL High-density lipoprotein, LDL Low-density lipoprotein